Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Aprea Therapeutics in connection with its EUR 50 million financing
Mandate

Vinge has advised Aprea Therapeutics in connection with its EUR 50 million financing

December 04, 2018 Banking and Finance

Aprea Therapeutics AB, with headquarters in Stockholm (Solna), is a biotechnology company focused on the discovery and development of new cancer drugs reactivating the tumour suppressor protein p53. 

Vinge has advised Aprea Therapeutics in connection with its EUR 50 million series C financing round, led by the Redmile Group and with participation by the new investor Rock Springs Capital and the existing shareholders 5AM Ventures, Versant Ventures, HealthCap, Sectoral Asset Management, Karolinska Development AB.

Vinge’s team consisted of Kristina Ekberg, Peter Issa and Tove Lövgren Frisk. 

Related

Vinge has advised Stenhus Fastigheter i Norden AB in connection with their uplisting to Nasdaq Stockholm

 Vinge has advised Stenhus Fastigheter i Norden AB (publ) (“Stenhus Fastigheter” or the “Company”) in connection with the Company's uplisting to Nasdaq Stockholm. The first day of trading on Nasdaq Stockholm was 18 December 2024.
December 20, 2024

Vinge advised Platzer on its sale of building rights in Södra Änggården to the property developer Bonava

 The transaction is being carried out through a company acquisition at an underlying property value of SEK 186 million.
December 20, 2024

Vinge represents IKEA Forestry Investment AB in connection with the acquisition of forest and land in Latvia

 Vinge assists IKEA Forestry Investment AB (a company within the Inter IKEA group) in the acquisition of 100% of the shares in the two Latvian companies SIA "Latvijas Mežu Aģentūra" and SIA "Vadakstes Meži" (the “Companies") from Skogsfond Baltikum AB (publ). The Companies own a total of 8,080 hectares of forest and land in Latvia.
December 16, 2024